Bench Side Story continues with Dr Kelsie Raspin, a dedicated Postdoctoral Research Fellow specialising in Cancer Genetics at Menzies Institute for Medical Research, University of Tasmania, AUSTRALIA
Her primary research focus revolves around bridging a critical knowledge gap in the understanding of genetic alterations implicated in prostate cancer initiation and its progression into metastatic forms.
Driven by an unwavering commitment to equitable access to genomic innovation in clinical cancer care, Kelsie aspires to enhance health outcomes not only for her fellow Tasmanians but also for individuals worldwide.
Kelsie’s research is funded through an RHH Research Foundation grant.
-
Behavioural science in cancer screening, control and communication
Dr Dodd has an established international reputation as a behavioural scientist in cancer control and communication. Since completing her PhD in 2016, Dr Dodd has been awarded a three-year University of Sydney Postdoctoral Research Fellowship (2018-2021) and a three-year Research Fellowship at The Daffodil Centre (current). Dr Dodd is the co-chair of the ‘Strengthening and optimising approaches to cancer prevention, screening, and early detection’ hub at The Daffodil Centre (with more than 130 staff and students).
-
Investigating invasive lobular carcinoma and metaplastic breast cancer sub-types
Assoc Prof McCart Reed is the scientific lead on an MRFF-funded (Medical Research Future Fund) genomics program investigating the potential for the application of Whole Genome Sequencing in the breast cancer care pathway in Australia, ‘Q-IMPROvE’. She applies genomics and spatial transcriptomics methodologies to archival clinical samples to understand the differences between tumour types and their potential for treatment. Amy is passionate about clinical research, biobanking and precision oncology. In addition to her breast cancer research portfolio, she is on the steering committee for the Brisbane Breast Bank and the Scientific Advisory Board for Breast Cancer Trials.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
